usp31nf26s2_Carrageenan

合集下载

缩宫素USP32中文翻译

缩宫素USP32中文翻译

缩宫素USP32C43H66N12012S2 分子量:1007.19缩宫素为多肽类激素药,刺激子宫平滑肌收缩,刺激乳腺的平滑肌收缩。

本品由化学合成或自人类可食用的家畜的脑垂体后叶中提取。

每1mg中不少于400个单位。

包装与贮藏:保存于Type1玻璃容器,密封,冷藏微生物限度检查实验和特殊微生物检查实验:每克中细菌总量不应超过200cfu。

若药物来源于家畜,则不应含有沙门氏菌和大肠杆菌。

鉴别:A:在含量测定项下记录的色谱图中,供试品溶液主峰的保留时间应与对照品溶液主峰的保留时间一致。

B:缩宫素生物测定法,应有子宫收缩的反应。

取体重120~200g,动情前期的大鼠的子宫。

配制子宫肌蓄养液:取氯化钠9.0g,氯化钾0.42g,氯化钙0.16g,碳酸氢钠0.50g,葡萄糖0.25g和氯化镁0.0053g,,溶解于1000ml水中,向蓄养液中通入95%的氧气和5%的二氧化碳气体。

将子宫的一端固定于恒温水浴装置中,向水浴装置中加入一定量的蓄养液,温度保持在32℃。

依次注入两种浓度的标准品稀释液,记录子宫收缩情况,能使子宫肌产生次极大收缩的为适宜的稀释液。

然后放去蓄养液并用蓄养液洗涤一次,再加入等量蓄养液,每次给药应在前一次反应恢复稳定后进行。

用适宜的稀释剂将供试品稀释,供试品溶液与标准品溶液各取两个剂量,注入水浴中,供试品溶液与标准品溶液使肌肉收缩的幅度相近。

升压物质检查(动物来源药物):配制标准品稀释溶液,精密量取血管升压素标准品适量,制成每1ml中含有0.1单位的溶液。

供试品溶液每1ml中不应超过0.1个单位。

方法同含量测定。

杂质:供试品溶液中的各杂质峰面积的和不应大于对照溶液主峰的5%(0.05倍)含量测定:色谱条件与系统适应性:用十八烷基硅烷键合硅胶为填充剂(粒径5µm),色谱柱(4.6mm×12.0cm),检测波长220nm,柱温为室温,流速1.5ml/min。

取对照品溶液100µl,注入色谱仪,重复进样,峰面积的RSD值不得大于2.0%。

卡培他滨USP标准中文翻译

卡培他滨USP标准中文翻译

卡培他滨kapeitabingCapecitabineC15H22FN3O6 359.35本品为氨基甲酸,[1-(5-脱氧-β-D-呋喃核糖)-5-氟-1 ,2-二氢-2 -氧-4-嘧啶]-,戊酯.戊烷基1-(5-脱氧-β-D-呋喃核糖-5-氟-1 ,2-二氢-2-氧代-4-胞嘧啶核苷。

按干燥品计算,含C15H22FN3O6应不少于98%不大于102%。

【性状】比旋度:精密称取适量本品,加无水甲醇溶解并稀释成每1ml含10mg的溶液。

依法测定(USP32-NF27,781S),比旋度为+96.0⁰至 +100.0⁰【鉴别】(1)红外吸收图谱——将2mg本品混合在300mg溴化钾中压片。

本品的红外光吸收图谱应与对照的图谱一致(USP32-NF27,197K)。

(2)在含量测定项下记录的色谱图中,供试品溶液主峰的保留时间应与对照品主峰的保留时间一致。

【检查】水分:依法检查(USP32-NF27,921,Method Ic),水分不得过0.3%炽灼残渣:依法检查(USP32-NF27,281),遗留残渣不得过0.1%重金属:依法检查(USP32-NF27,231,MethodⅡ),含重金属不得过百万分之二十有关物质:稀释液、溶液A、溶液B、峰鉴别溶液和色谱条件:按含量测定项下的要求对照溶液的制备:使用按含量测定项下的要求制备的对照品溶液供试溶液的制备:使用按含量测定项下的要求制备的供试品溶液测定法:分别量取等量的(约10μl)的对照溶液和供试溶液注入液相色谱仪,记录色谱图并测量各峰面积,按以下公式计算卡培他滨中各杂质的百分含量:100(1/F)(C S / C U)(r I/r S)式中,F是表1中各杂质的相对响应因子,C S是对照溶液中USP卡培他滨对照品的浓度,单位mg/ml;C U是供试溶液中卡培他滨的浓度,单位mg/ml; r I供试溶液中各杂质的峰面积;r S是对照溶液中卡培他滨的峰面积。

各杂质的限量也在表1中列出。

usp31nf26s2_Lead 251

usp31nf26s2_Lead 251

251 LEADThe imposition of stringent limits on the amounts of lead that may be present in pharmaceutical products has resulted in the use of two methods, of which the one set forth following depends upon extraction of lead by solutions of dithizone. For determination of the content of heavy metals generally, expressed as a lead equivalent, see Heavy Metals 231.Select all reagents for this test to have as low a content of lead as practicable, and store all reagent solutions in containers of borosilicate glass. Rinse thoroughly all glassware with warm dilute nitric acid (1 in 2), followed by water.Special Reagents—AMMONIA-CYANIDE SOLUTION— Dissolve 2 g of potassium cyanide in 15 mL of ammonium hydroxide, and dilute with water to 100 mL.AMMONIUM CITRATE SOLUTION— Dissolve 40 g of citric acid in 90 mL of water. Add 2 or 3 drops of phenol red TS, then cautiously add ammonium hydroxide until the solution acquires a reddish color. Remove any lead that may be present by extracting the solution with 20-mL portions of Dithizone Extraction Solution (see below), until the dithizone solution retains its orange-green color.DILUTED STANDARD LEAD SOLUTION— Dilute an accurately measured volume of StandardLead Solution (see Heavy Metals 231) [containing 10 µg of lead per mL], with 9 volumes of dilute nitric acid (1 in 100) to obtain a solution that contains 1 µg of lead per mL.DITHIZONE EXTRACTION SOLUTION— Dissolve 30 mg of dithizone in 1000 mL of chloroform, and add 5 mL of alcohol. Store the solution in a refrigerator.Before use, shake a suitable volume of the dithizone extraction solution with about half its volume of dilute nitric acid (1 in 100), discarding the nitric acid.HYDROXYLAMINE HYDROCHLORIDE SOLUTION— Dissolve 20 g of hydroxylamine hydrochloride in sufficient water to make approximately 65 mL. Transfer to a separator, add 5 drops of thymol blue TS, then add ammonium hydroxide until the solution assumes a yellow color. Add 10 mL of sodium diethyldithiocarbamate solution (1 in 25), mix, and allow to stand for 5 minutes. Extract this solution with successive 10- to 15-mL portions of chloroform until a 5-mL portion of the chloroform extract does not assume a yellow color when shaken with cupric sulfate TS. Add 3 N hydrochloric acid until the solution is pink (if necessary, add 1 or 2 drops more of thymol blue TS), and then dilute with water to 100 mL.POTASSIUM CYANIDE SOLUTION— Dissolve 50 g of potassium cyanide in sufficient water to make 100 mL. Remove the lead from this solution by extraction with successiveportions of Dithizone Extraction Solution, as described under Ammonium Citrate Solution above, then extract any dithizone remaining in the cyanide solution by shaking with chloroform. Finally dilute the cyanide solution with sufficient water so that each 100 mL contains 10 g of potassium cyanide.STANDARD DITHIZONE SOLUTION— Dissolve 10 mg of dithizone in 1000 mL of chloroform. Keep the solution in a glass-stoppered, lead-free bottle, suitably wrapped to protect it from light, and store in a refrigerator.Test Preparation— [NOTE—If, in the following preparation, the substance under test reacts too rapidly and begins charring with 5 mL of sulfuric acid before heating, use instead 10 mL of cooled dilute sulfuric acid (1 in 2), and add a few drops of the hydrogen peroxide before heating.] Where the monograph does not specify preparation of a solution, prepare a Test Preparation as follows. [Caution—Exercise safety precautions in this procedure, as some substances may react with explosive violence when digested with hydrogen peroxide. ] Transfer 1.0 g of the substance under test to a suitable flask, add 5 mL of sulfuric acid and a few glass beads, and digest on a hot plate in a hood until charring begins. Other suitable means of heating may be substituted. (Add additional sulfuric acid, if necessary, to wet the substance completely, but do not add more than a total of 10 mL.) Add, dropwise and with caution, 30 percent hydrogen peroxide, allowing the reaction to subside and again heating between drops. Add the first few drops very slowly, mix carefully to prevent a rapid reaction, and discontinue heating if foaming becomes excessive. Swirl the solution in the flask to prevent unreacted substance from caking on the walls of the flask. [NOTE—Add peroxide whenever the mixture turns brown or darkens.] Continue the digestion until the substance is completely destroyed, copious fumes of sulfur trioxide are evolved, and the solution is colorless. Cool, cautiously add 10 mL of water, evaporate until sulfur trioxide again is evolved, and cool. Repeat this procedure with another 10 mL of water to remove any traces of hydrogen peroxide. Cautiously dilute with 10 mL of water, and cool.Procedure— Transfer the Test Preparation, rinsing with 10 mL of water, or the volume of the prepared sample specified in the monograph to a separator, and, unless otherwise directed in the monograph, add 6 mL of Ammonium Citrate Solution and 2 mL of Hydroxylamine Hydrochloride Solution. (For the determination of lead in iron salts use 10 mL of Ammonium Citrate Solution.) Add 2 drops of phenol red TS, and make the solution just alkaline (red in color) by the addition of ammonium hydroxide. Cool the solution if necessary, and add 2 mL of Potassium Cyanide Solution. Immediately extract the solution with 5-mL portions of Dithizone Extraction Solution, draining off each extract into another separator, until the dithizone solution retains its green color. Shake the combined dithizone solutions for 30 seconds with 20 mL of dilute nitric acid (1 in 100), and discardthe chloroform layer. Add to the acid solution 5.0 mL of Standard Dithizone Solution and 4 mL of Ammonia-Cyanide Solution , and shake for 30 seconds: the color of the chloroform layer is of no deeper shade of violet than that of a control made with a volume of Diluted Standard Lead Solution equivalent to the amount of lead permitted in the sample under examination, and the same quantities of the same reagents and in the same manner as in the test with the sample.Auxiliary Information— Before contacting USP, have you checked for your question in the FAQs ?USP31–NF26 Page 135 Topic/Question Contact Expert Committee Monograph Kahkashan Zaidi, Ph.D.Senior Scientist1-301-816-8269(GC05) General Chapters 05。

美国药典USP31-71-无菌检查法-双语版

美国药典USP31-71-无菌检查法-双语版

美国药典USP31-NF26无菌检查法《71》.doc71 STERILITY TESTS 无菌检查法Portions of this general chapter have been harmonized with the corresponding texts of the European Pharmacopeia and/or the Japanese Pharmacopeia. Those portions that are not harmonized are marked with symbols () to specify this fact.此通则的各部分已经与欧洲药典和/或日本药典的对应部分做了协调。

不一致的部分用符号()来标明。

The following procedures are applicable for determining whether a Pharmacopeial article purporting to be sterile complies with the requirements set forth in the individual monograph with respect to the test for sterility. Pharmacopeial articles are to be tested by the Membrane Filtration method under Test for Sterility of the Product to be Examined where the nature of the product permits. If the membrane filtration technique is unsuitable, use the Direct Inoculation of the Culture Medium method under Test for Sterility of the Product to be Examined. All devices, with the exception of Devices with Pathways Labeled Sterile, are tested using the Direct Inoculation of the Culture Medium method. Provisions for retesting are included under Observation and Interpretation of Results.下面这些步骤适用于测定是否某个用于无菌用途的药品是否符合其具体的各论中关于无菌检查的要求。

非那雄胺质量标准USP32

非那雄胺质量标准USP32

FinasterideC 23H 36N 2O 2 372.554-Azaandrost-1-ene-17-carboxamide, N -(1,1-dimethylethyl)-3-oxo-, (5,17)-. N -tert -Butyl-3-oxo-4-aza-5-androst-1-ene-17-carboxamide [98319-26-7]. » Finasteride contains not less than 98.5 percent and not more than 101.0 percent of C 23H 36N 2O 2, calculated on the anhydrous basis.Packaging and storage— Preserve in tight containers, and store at controlled room temperature. USP Reference standards 11—USP Finasteride RS .Identification—A: Infrared Absorption 197M .B: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay . Specific rotation 781S : between 56.0 and 60.0, determined at 405 nm.Test solution: 10 mg per mL, in methanol.Water, Method I 921: not more than 0.3%. Residue on ignition 281: not more than 0.1%.Heavy metals, Method II 231: 0.001%.Chromatographic purity—Mobile phase— Prepare a filtered and degassed mixture of water, tetrahydrofuran, and acetonitrile (8:1:1). Make adjustments if necessary (see System Suitability under Chromatography 621).Diluting solution— Prepare a solution of water and acetonitrile (1:1). Standard solution— Dissolve an accurately weighed quantity of USP Finasteride RS in Diluting solution, and dilute quantitatively, and stepwise if necessary, with Diluting solution to obtain a solution having a known concentration of about 1.0 mg per mL.Test solution— Transfer about 100 mg of Finasteride, accurately weighed, to a 100-mL volumetric flask, dissolve in and dilute with Diluting solution to volume, and mix.Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 210-nm detector and a 4.6-mm × 30-cm column that contains 4-µm packing L1. The flow rate is about 1.5 mL per minute. The column temperature is maintained at 60. Chromatograph the Standard solution, and record the peak responses as directed for Procedure: the column efficiency is not less than 10,000 theoretical plates; and the tailing factor is not more than 1.3.Procedure— Inject a volume (about 15 µL) of the Test solution into the chromatograph, record the chromatograms, and measure the peak responses. Calculate the percentage of each impurity in the portion of Finasteride taken by the formula:100(r i / r s)in which r i is the peak response for each impurity, and r s is the sum of the responses of all peaks: not more than 0.5% of any individual impurity is found; and not more than 1.0% of total impurities is found.Assay—Mobile phase— Prepare a filtered and degassed mixture of water and tetrahydrofuran (4:1). Make adjustments if necessary (see System Suitability under Chromatography 621).Diluting solution— Prepare a solution of water and acetonitrile (1:1). Standard preparation— Dissolve an accurately weighed quantity of USP Finasteride RS in Diluting solution, and dilute quantitatively, and stepwise if necessary, with Diluting solution to obtain a solution having a known concentration of about 200 µg per mL.Assay preparation— Transfer about 20 mg of Finasteride, accurately weighed, to a 100-mL volumetric flask, dissolve in and dilute with Diluting solution to volume, and mix.Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 215-nm detector and a 3.0-mm × 3.0-cm column that contains 3-µm packing L7. The flow rate is about 3 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the column efficiency is not less than 1800 theoretical plates; the tailing factor is not more than 1.3; and the relative standard deviation for replicate injections is not more than 1.0%.Procedure— Separately inject equal volumes (about 10 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of C23H36N2O2 in the portion of Finasteride taken by the formula:100C(r U / r S)in which C is the concentration, in mg per mL, of USP Finasteride RS in the Standard preparation; and r U and r S are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.Auxiliary Information— Please check for your question in the FAQs before contacting USP.Topic/Question Contact ExpertCommitteeMonograph Daniel K. Bempong,Ph.D.Senior Scientist1-301-816-8143 (MDPS05) Monograph Development-Pulmonary and SteroidsReference Standards Lili Wang, Technical Services Scientist 1-301-816-8129 RSTech@USP32–NF27 Page 2377Pharmacopeial Forum: Volume No. 27(2) Page 2144Chromatographic Column—FINASTERIDEChromatographic columns text is not derived from, and not part of, USP 32 or NF 27.。

美国药典USP31-NF26色谱《621》

美国药典USP31-NF26色谱《621》

621CHROMATOGRAPHY色谱法INTRODUCTION介绍This chapter defines the terms and procedures used in chromatography and provides general information. Specific requirements for chromatographic procedures for drug substances and dosage forms, including adsorbent and developing solvents, are given in the individual monographs.此章节定义了色谱法中用到的术语和步骤,并提供了通用信息。

对于原料药和成药的色谱步骤的具体要求,包括吸附剂和展开溶剂,在具体各论中给出。

Chromatography is defined as a procedure by which solutes are separated by a dynamic differential migration process in a system consisting of two or more phases, one of which moves continuously in a given direction and in which the individual substances exhibit different mobilities by reason of differences in adsorption, partition, solubility, vapor pressure, molecular size, or ionic charge density. The individual substances thus separated can be identified or determined by analytical procedures.色谱法是应用溶质在两相或多相系统中的差速迁移来进行分离的技术,其中一相持续地向特定方向移动,而由于物质在吸附性、分配、溶解性、气体压力、分子大小、或离子电荷密度上的差异,会显示出不同的移动性。

美国USP色谱柱编号对照表

美国USP色谱柱编号对照表

美国USP色谱柱编号对照表L1:十八烷基键合多孔硅胶或无机氧化物微粒固定相,简称C18或ODSL2:30~50um表面多孔薄壳型键合C18(ODS)固定相L3:多孔硅胶微粒即一般的硅胶柱L4:30~50um表面多孔薄壳型硅胶L5:30~50um表面多孔薄壳型氧化铝L6:30~50um实心微球表面包覆磺化碳氟聚合物-强阳离子交换固定相L7:全多孔硅胶微粒键合C8官能团固定相简称C8柱L8:全多孔硅胶微粒键合非交联NH2固定相简称NH2柱L9:强酸性阳离子交换基团键合全多孔不规则形硅胶固定相L10:多孔硅胶微球键合氰基固定相(CN)简称CN柱L11:键合苯基多孔硅胶微球固定相简称苯基柱L12:无孔微球键合季胺功能团的强阴离子填料L13:三乙基硅烷化学键合全多孔硅胶微球固定相(C1)简称C1柱L14:10um硅胶化学键合强碱性季铵盐阴离子交换固定相简称SAX柱L15:已基硅烷化学键合全多孔硅胶微球固定相简称C6柱L16:二甲基硅烷化学键合全多孔硅胶微粒固定相L17:氢型磺化交联苯乙烯-二乙烯基苯共聚物,强阳离子交换树脂L18: 3~10um全多孔硅胶化学键合胺基(NH2)和氰基(CN)L19:钙型磺化交联苯乙烯-二乙烯基苯共聚物,强阳离子交换树脂L20:二羟基丙烷基化学键合多孔硅胶微球固定相(Diol)简称二醇基柱L21:刚性苯乙烯-二乙烯基苯共聚物微球L22:带有磺酸基团的多孔苯乙烯阳离子交换树脂L23:带有季胺基团的聚甲基丙烯酸甲酯或聚丙烯酸酯多孔离子交换树脂L24:表面含有大量羟基的半刚性聚乙烯醇亲水凝胶L25:聚甲基丙烯酸酯树脂交联羟基醚(表面含有残余羧基功能团)树脂。

能分离分子量100~5000MW范围的水溶性中性、阳离子型及阴离子型聚合物(用聚氧乙烯测定)的固定相L26:丁基硅烷化学键合全多孔硅胶微球固定相L27:30~50um的全多孔硅胶微粒L28:多功能载体,100?的高纯硅胶加以氨基键合以及C8反相键合的官能团L29: 氧化铝,反相键合,含碳量低,氧化铝基聚丁二稀小球,5um,孔径80?L30: 全多孔硅胶键合乙基硅烷固定相L31: 季胺基改性孔径2000?的交联苯乙烯和二乙烯基苯(55%)强阴离子交换树脂L32: L-脯氨酸铜配合物共价键合于不规则形硅胶微粒的配位体的交换手性色谱填料L33: 能够分离分子量4000~40000MW范围蛋白质分子的球形硅胶固定相,pH稳定性好L34:铅型磺化交联苯乙烯-二乙烯基苯共聚物强阳离子交换树脂,9um球形L35:锆稳定的硅胶微球键合二醇基亲水分子单层固定相,孔径150?L36: 5um胺丙基硅胶键合L-苯基氨基乙酸-3,5二硝基苯甲酰L37:适合分离分子量2000~40,000Mw的聚甲基丙烯酸酯凝胶L38:水溶性甲基丙烯酸酯基质SEC色谱柱L39:亲水全多孔聚羟基甲基丙烯酸酯色谱柱L40:Tris 3,5-二甲基苯基氨基甲酸酯纤维素涂覆多孔硅胶微球L41:球形硅胶表面固定α1酸糖蛋白固定相L42: C8和C18硅烷化学键合多孔硅胶固定相L43: 硅胶微球键合五氟代苯基固定相L44: 多功能固定相,60 ?高纯硅胶基质键合磺酸阳离子交换功能团和C8反相功能团L45: β-环糊精键合多孔硅胶微球L46: 季胺基改性苯乙烯-二乙烯基苯聚合物微球。

氨苄西林钠(中文版)-USP31.doc

氨苄西林钠(中文版)-USP31.doc

氨苄西林钠Ampicillin Sodium(USP31-NF26第1420页)C16H18N3NaO4S 371.39按无水物计算,氨苄西林钠的效价以氨苄西林(C16H19N3O4S)计,每1mg 应为845µg~988µg。

[包装和贮存]贮存在密闭容器中。

[标贴] 本品用于制备注射剂时,标贴上应注明本品无菌或本品在制备注射剂过程中须经进一步的处理。

[USP标准物质] <11> USP氨苄西林RS、USP氨苄西林钠RS、USP内毒素RS。

[鉴别] A:红外光吸收图谱<179M>。

B:显钠盐反应<191>。

[结晶性] <695> 应符合要求。

(注-如为冻干粉则可不检此项)[pH] <791> 取本品,加水制成每1mL中含10.0mg氨苄西林的溶液,振摇使溶解,pH值应为8.0~10.0。

[水分] <921> 不得过2.0%。

方法Ⅰ。

[二甲基苯胺] <223> 应符合要求。

内标溶液、对照品溶液、供试品溶液的制备方法如下:内标溶液:取N,N-二乙基苯胺75mg,加1mol/L盐酸溶液使溶解,用水逐步稀释制成每1mL中约含30µg的溶液。

对照品溶液:取N,N-二甲基苯胺50.0mg,精密称定,置50mL量瓶中,加1mol/L盐酸溶液25mL振摇混匀后,用水稀释至刻度,摇匀,精密量取2mL,置100mL量瓶中,用水稀释至刻度,摇匀,精密量取1mL,置适宜的离心管中,精密加入1.25mol/L氢氧化钠溶液、内标溶液和环己烷各1mL,强烈振摇1分钟然后离心,取上清液,作为对照品溶液。

供试品溶液:取本品1.0g,精密称定,置适宜的离心管中,加1.25mol/L 氢氧化钠溶液2mL,振摇使溶解,精密加入内标溶液1mL和环己烷1mL,强烈振摇1分钟然后离心,取上清液,作为供试品溶液。

色谱系统(见色谱法<621>):气相色谱仪应配有火焰离子化检测器和2mm×2m的填充有上涂3%液相G3的硅烷化S1A的色谱柱。

美国药典USPNF色谱

美国药典USPNF色谱

美国药典USPNF色谱随着药物研究和生产的不断发展,化学分析成为药物质量控制的重要手段之一。

毒理学和药物安全性评估需要准确的组成分析和含量测定,而且质量控制必须遵循有国际影响力的标准。

美国药典(USP)是一个评估和监管药物质量的非营利组织,在美国以及全球范围内都被广泛认可,它为全球药物和食品行业的质量标准制定提供了重要的参考依据。

其中与色谱分析相关的内容被编入美国药典的色谱单元,成为美国药典色谱(USP-NF)。

美国药典色谱(USPNF)是美国药典所编制的、与色谱分析相关的内容所组成的分册。

该分册覆盖了各种技术方法和分析技巧,在色谱学分析方面,主要包含了高效液相色谱(HPLC)和气相色谱(GC)两类。

HPLC作为一种重要的分离方法,广泛应用于药物分析、生化分析、食品分析等领域。

美国药典色谱通过列出HPLC检测专用的药物物质,以及制定适宜的HPLC方法进行药物物质分析,以保障药品质量。

美国药典色谱还包含针对气相色谱分析方法的指南。

GC作为一种分离技术,已经成为许多行业中最常用的分析方法之一。

通过美国药典颁布的气相色谱方法,可以保证药品的质量,满足全球质量标准,在药物的生产和分析中发挥着重要的作用。

除此之外,USPNF还包含了一些在特殊情况下使用的其他色谱方法,如离子交换色谱、薄层色谱等。

在它们列举的分析方法中,可以为药品分析提供多种参考依据,同时保障质量的一致性和准确性。

美国药典色谱(USPNF)不仅仅是一个规范和标准操作指南,它还为药物制造商提供了一个国际公认的质量控制体系。

在全球化的药品市场中,美国药典色谱既刻画了一种药品质量目标,也规定了药品质量标准,具有非常重要的临床和药学意义。

同时,由于美国药典色谱列举的方法都是公认的正规方法,因此在使用美国药典列举的分析方法时,药品制造商可以对质量及其相应的操作有更好的把控,同时也为药品设计提供更多参考依据。

总之,美国药典色谱作为美国药典中的一个重要分册,可以为全球药品和食品行业提供良好的质量和标准化分析方法,保障药品和食品的安全性和质量一致性。

usp美国药典结构梳理

usp美国药典结构梳理

USP35-NF-30结构整理vivi2010-10-02USP总目录:1 New Official Text修订文件加快修订过程包括勘误表,临时修订声明(IRAS),修订公告。

勘误表,临时修订声明,修订公告在USP网站上New Official Text部分刊出,勘误表,临时修订公告也会在PF上刊出2front matter前言药典与处方集增补删减情况,审核人员,辅料收录情况3凡例药典,1标题和修订2 药典地位和法律认可3标准复合性4专论和通则5 专论组成6 检验规范和检验方法7 测试结果8 术语和定义9 处方和配药10 包装存储与标签4通则4.1章节列表4.2一般检查和含量测定(章节编号小于1000)检查和含量分析的一般要求检查和含量分析的仪器,微生物检查,生物检查和含量测定,化学检查和含量测定,物理检查和测定4.3一般信息(章节号大于1000)5食物补充剂通则6试剂(试剂,指示剂,溶液等)7参考表性状描述和溶解性查询表(按字母顺序)8食品补充剂各论(字母顺序)9NF各论(辅料标准)10 USP各论11术语附件:通则的章节中文目录(使用起来比较方便,直接找对应章节号即可)一、通用试验和检定(1)试验和检定的总要求1 注射剂11 参比标准物(2)试验和检定的装置16 自动分析方法21 测温仪31 容量装置,如容量瓶、移液管、滴定管,各种规格的误差限度41 砝码和天平(3)微生物学试验51 抗菌效力试验55 生物指示剂:耐受性能试验61 微生物限度试验61 非灭菌制品的微生物检查:计数试验62 非灭菌制品的特定菌检查,如大肠杆菌、金葡菌、沙门氏菌等71 无菌试验(4)生物学试验和检定81 抗生素微生物检定85 细菌内毒素试验87 体外生物反应性试验:检查合成橡胶、塑料、高聚物对哺乳类细胞培养的影响88 体内生物反应性试验:检查上述物质对小鼠、兔iv、ip或肌内植入的影响91 泛酸钙检定111 生物检定法的设计和分析115 右泛醇检定121 胰岛素检定141 蛋白质——生物适应试验,用缺蛋白饲料大鼠,观察水解蛋白注射液和氨基酸混合物的作用151 热原检查法161 输血、输液器及类似医疗装置的内毒素、热原、无菌检查171 维生素B12 活性检定(5)化学试验和检定A 鉴别试验181 有机含氮碱的鉴别191 一般鉴别试验193 四环素类鉴别197 分光光度法鉴别试验201 薄层色谱鉴别试验B 限量试验206 铝211 砷221 氯化物和硫酸盐223 二甲基苯胺226 4-差向脱水四环素231 重金属241 铁251 铅261 汞271 易炭化物试验281 炽灼残渣291 硒C 其他试验和检定301 中和酸能力311 藻酸盐检定331 苯丙胺检定341 多剂量容器注射剂中所加防腐剂含量的气相色谱或极谱法测定345 枸橼酸与其盐以及磷酸盐检定351 甾体检定361 巴比妥酸盐检定371 维生素B12放射示踪物检定381 注射剂橡胶塞检查391 肾上腺素检定401 脂肪和固定油检查411 叶酸检定425 抗生素碘量法检定429 微粒大小的光衍射测量431 甲氧基测定441 烟酸或烟酰胺检定451 亚硝酸盐滴定461 氮测定466 普通杂质的薄层色谱法检查467 有机挥发性杂质检查法467 残留溶剂测定471 氧瓶燃烧法481 核黄素检定501 有机含氮碱的盐511 单一甾醇检定521 磺胺类的色谱法检定531 硫胺检定541 滴定法554 α-生育酚检定561 植物来源物品的一般检查项目563 植物来源物品的各种鉴别项目(植物学部分、显微鉴别、化学鉴别)565 植物提取物的一般提取方法和要求571 维生素A检定:化学法、色谱法581 维生素D检定:色谱法、化学法、生物法591 锌测定(6)物理试验和测定601 气雾剂、鼻喷雾剂、计量吸入剂和干粉吸入剂的各项检测611 乙醇含量测定:蒸馏法、气一液色谱法616 固体的疏松密度和叩击密度测定621 色谱法631 色度检查和标准641 溶解的完全性检查643 总有机炭测定645 水导电性测定651 冻凝温度的测定661 药用容器的检测项目要求671 盛装胶囊和片剂容器加盖后对湿气的通透性试验691 棉花吸附性和纤维长度测定695 结晶性检查696 用溶液测热法测定结晶度698 装量检查699 固体密度(粉粒密度测定法)701 崩解试验711 溶出试验721 蒸馏温度范围(馏程)测定724 通过透皮转运系统药物的释放726 电泳727 毛细管电泳730 等离子体光谱化学检查法731 干燥失重733 炽灼失重736 质谱法741 熔点范围或温度的测定751 眼膏中的金属颗粒测定755 最低装量检查法761 核磁共振771 眼用软膏的要求776 光学显微镜微粒检查法781 旋光度检查785 渗透压摩尔浓度测定法786 用分析筛测量颗粒大小的分布788 注射液中微粒物质测定法789 眼用溶液中微粒物质测定法791 PH测定法795 非灭菌制剂的药物配制要求797 灭菌制剂的药物配制要求801 极谱法811 粉末细度测定821 放射活性药物823 正电子发射层析X线摄影(PET)所用放射性药物的配制831 折光指数测定841 比重测定846 粉末的比表面积测定851 分光光度法与光散射861 外科缝合线直径检查871 附有针的缝合线检查881 外科缝合线、纺织品与膜片的弹力强度检查891 热分析:温度变化、热解重量分析、易熔杂质分析等905 剂量单位的均匀性检查(含量均匀度、装量差异)911 黏度测定921 药品含水量的测定941 结晶型药物的X线衍射分析二、通用资料1010 数据分析方法1015 诊断用放射药的自动合成装置1031 药用容器、医用装置和植入物所用材料的生物相容性检查1035 灭菌用生物指示剂1041 生物制品的批签发1043 细胞、基因和组织工程产品的辅助材料1045 生物技术产品1046 细胞和基因治疗产品1047 生物技术产品的检验法1048 生物技术产品的质量——重组DNA蛋白质产品生产所用细胞表达构成的分析1049 生物技术产品的稳定性试验1050 人或动物来源的细胞系所得生物技术产品的病毒安全性评价1051 玻璃仪器清洗方法1061 颜色的仪器测量1065 离子色谱1072 消毒剂与防腐剂1074 赋形剂生物学安全性评价指导原则1075 复方药物配制质量规范1078 大批量药用赋形剂的生产质量规范1079 储存与运输的质量规范1081 明胶的凝胶强度1086 药品中的杂质来源1087 特性溶出1088 剂型的体外和体内评价1090 体内生物等效性试验指导原则1091 剂型中含有无活性组分的标示1092 溶出试验方法的发展和验证1101 药用滴管1111 非灭菌药品的微生物特征1111 非灭菌药品的微生物特征检查:药用原料和药物制剂的判定标准1112 非灭菌药品中的水活性测定,即在同一温度时,药品中水的蒸气压与纯水蒸气压之比,它等于药品在密闭系统中产生相对湿度的1%1116 清洁室和其他受控环境的微生物评价1117 微生物实验室的质量规范(GLP)1118 监控装置:时间、温度、湿度1119 近红外分光光度法1120 拉曼(Raman)分光光度法1121 药品命名法1136 药品包装:应用单元1146 口服固体药分装在单疗程剂量容器中的检查方法1150 药物剂型的稳定性1151 药物剂型1160 处方调配的药学计算1171 原料药的位相溶解度分析1174 粉末流动性测定1176 处方天平和容量装置1177 包装质量规范1178 分装质量规范1181 扫描电子显微镜1191 调剂工作中的药品稳定性保持1196 药典协调(指欧洲药典、美国药典、日本药局方三方机构讨论协调的原则和方法)1207 灭菌产品包装:完整性评价1208 灭菌试验:隔离系统的验证1209 灭菌:化学和物理化学的指示剂与积分仪1211 药典收载品种的灭菌和灭菌保证1216 片剂脆性检查1221 茶匙(家用标准为5 ml,可作为病人口服液体药物的量具,误差应小于10%)1222 药品灭菌终点的放行参数1223 微生物替代方法的验证1225 药典方法的验证1227 在抗菌效力、微生物限度、灭菌等试验中,微生物的恢复验证1230 血液透析用水1231 药用水的制备和要求1241 在制药系统中,水—固体的相互作用1251 用分析天平称量的要求1265 书写药物处方的指导原则三、饮食增补剂2021 营养和饮食增补剂的微生物计数试验2022 营养和饮食增补剂中不允许存在的微生物(如金葡菌、沙门氏菌、大肠杆菌、梭状芽胞杆菌属)检查法2023 非灭菌的营养和饮食增补剂中的微生物特征2030 植物来源物品的增补资料2040 饮食增补剂的崩解和溶出检查2091 饮食增补剂的重(装)量差异检查2750 饮食增补剂的生产条件与质量要求(与药品有别)。

USP美国药典70种农残检测限度

USP美国药典70种农残检测限度
2
26
硫丹
Endosulfan (sum of isomers and endosulfan sulfate)
3
27
异狄氏剂
Endrin
0.05
28
乙硫磷
Ethion
2
பைடு நூலகம்29
乙嘧硫磷
Etrimphos
0.05
30
皮蝇硫磷
Fenchlorophos (sum of fenchlorophos and fenchlorophos-oxon)
1.5
36
氟氰戊菊酯
Flucytrinate
0.05
37
氟胺氰菊酯
τ-Fluvalinate(Tau-Fluvalinate (F) )
0.05
38
地虫硫磷
Fonophos
0.05
39
七氯
Heptachlor (sum of heptachlor, cis-heptachlorepoxide and trans-heptachlorepoxide)
3
除虫菊酯
Pyrethrins
65
喹硫磷
Quinalphos
0.05
66
五氯硝基苯
Quintozene (sum of quintozene, pentachloraniline and methyl penthachlorphenyl sulfide)
1
67
八氯二丙醚
S-421
0.02
68
四氯硝基苯
Bromide, inorganic (calculated as bromide ion)
50
7
乙基溴硫磷

替考拉宁USP标准

替考拉宁USP标准

Tartaric acid EUROPEAN PHARMACOPOEIA7.0TESTS Solution S .Dissolve 4.0g in carbon dioxide-free water R anddilute to 20mL with the same solvent.Appearance of solution .Solution S is not more opalescent than reference suspension II (2.2.1).Dextrins,gum,salts,sugars .To 2mL of solution S,add 2mL of ethanol (96per cent)R .The solution is clear.Add 1mL of ether R .The solution remains clear for at least 10min.Resins .To 5mL of solution S,add 5mL of water R .The mixture remains clear (2.2.1)for at least 15min.Loss on drying (2.2.32):maximum 12.0per cent,determined on 0.200g by drying at 105°C.Sulfated ash (2.4.14):maximum 0.1per cent,determined on 1.0g.STORAGEProtected from light.01/2008:0460corrected 6.0TARTARIC ACID Acidumtartaricum C 4H 6O 6M r 150.1[87-69-4]DEFINITION(2R ,3R )-2,3-Dihydroxybutanedioic acid.Content :99.5per cent to 101.0per cent (dried substance).CHARACTERSAppearance :white or almost white,crystalline powder orcolourless crystals.Solubility :very soluble in water,freely soluble in ethanol(96per cent).IDENTIFICATIONA.Solution S (see Tests)is strongly acid (2.2.4).B.It gives the reactions of tartrates (2.3.1).TESTSSolution S .Dissolve 5.0g in distilled water R and dilute to50mL with the same solvent.Appearance of solution .Solution S is clear (2.2.1)and not moreintensely coloured than reference solution Y 6(2.2.2,Method II ).Specific optical rotation (2.2.7):+12.0to +12.8(driedsubstance).Dissolve 5.00g in water R and dilute to 25.0mL with the same solvent.Oxalic acid :maximum 350ppm,calculated as anhydrous oxalicacid.Dissolve 0.80g in 4mL of water R .Add 3mL of hydrochloric acid R and 1g of zinc R in granules and boil for 1min.Allow to stand for 2min.Collect the liquid in a test-tube containing 0.25mL of a 10g/L solution of phenylhydrazine hydrochloride R and heat to boiling.Cool rapidly,transfer toa graduated cylinder and add an equal volume of hydrochloric acid R and 0.25mL of a 50g/L solutionofpotassium ferricyanide R .Shake and allow to stand for 30min.Any pink colour in the solution is not more intense than that in a standard prepared at the same time in the same manner using4mL of a 0.1g/L solution of oxalic acid R .Chlorides (2.4.4):maximum 100ppm.Dilute 5mL of solution S to 15mL with water R .Sulfates (2.4.13):maximum 150ppm.Dilute 10mL of solution S to 15mL with distilled water R .Calcium (2.4.3):maximum 200ppm.To 5mL of solution S add 10mL of a 50g/L solution of sodium acetate R in distilled water R .Heavy metals (2.4.8):maximum 10ppm.2.0g complies with test C.Prepare the reference solution using 2mL of lead standard solution (10ppm Pb)R .Losson drying (2.2.32):maximum 0.2per cent,determined on 1.000g by drying in an oven at 105°C.Sulfated ash (2.4.14):maximum 0.1per cent,determined on 1.0g.ASSAYDissolve 0.650g in 25mL of water R .Titrate with 1M sodium hydroxide using 0.5mL of phenolphthalein solution R as indicator,until a pink colour is obtained.1mL of 1M sodium hydroxide is equivalent to 75.05mgof C 4H 6O 6.01/2009:2358corrected 6.6TEICOPLANINTeicoplaninum3038See the information section on general monographs (cover pages)EUROPEAN PHARMACOPOEIA 7.0Teicoplanin DEFINITION Mixture of glycopeptides produced by certain strains of Actinoplanes teichomyceticus sp.;the 6principal components of the mixture are teicoplanin A 2-1to A 2-5and teicoplanin A 3-1.Fermentation product.Potency :minimum 900IU/mg (anhydrous and sodium chloride-free substance).CHARACTERS Appearance :yellowish,amorphous powder.Solubility :freely soluble in water,sparingly soluble in dimethylformamide,practically insoluble in ethanol (96per cent V/V ).IDENTIFICATION A.Infrared absorption spectrophotometry (2.2.24).Comparison :teicoplanin for identification CRS .B.Examine the chromatograms obtained in the test for composition and related substances.Results :the principal peaks (teicoplanins A 3-1,A 2-1,A 2-2,A 2-3,A 2-4and A 2-5)in the chromatogram obtained with the test solution are similar in retention time and size to the principal peaks in the chromatogram obtained with reference solution (a).TESTS Appearance of solution .The solution is clear (2.2.1)and not more intensely coloured than reference solution BY 3or B 4(2.2.2,Method I ).Dissolve 0.8g in 10mL of water R .pH (2.2.3):6.5to 7.5.Dissolve 0.50g in carbon dioxide-free water R and dilute to 10mL with the same solvent.Composition and related substances .Liquid chromatography (2.2.29):use the normalisation procedure.Test solution .Dissolve 0.100g of the substance to be examined in water R and dilute to 50.0mL with the same solvent.Reference solution (a).Dissolve 20mg of teicoplanin for identification CRS in water R and dilute to 10.0mL with the same solvent.Reference solution (b).Dilute 1.0mL of reference solution (a)to 10.0mL with water R .Dilute 1.0mL of this solution to 20.0mL with water R .Reference solution (c).Dissolve 50.0mg of mesityl oxide CRS in water R and dilute to 25.0mL with the same solvent.Dilute 1.0mL of the solution to 10.0mL with water R .Dilute 1.0mLof this solution to 100.0mL with water R .Column :—size :l =0.25m,Ø=4.6mm;—stationary phase :spherical end-capped octadecylsilyl silica gel for chromatography R (5μm).Mobile phase :—mobile phase A :mix 900mL of a 3.0g/L solution of anhydrous sodium dihydrogen phosphate R ,adjusted to pH 6.0with 1M sodium hydroxide ,and 100mL of acetonitrile R ;—mobile phase B :mix 300mL of a 3.0g/L solution of anhydrous sodium dihydrogen phosphate R ,adjusted to pH 6.0with 1M sodium hydroxide ,and 700mL of acetonitrile R ;Time(min)Mobile phase A (per cent V/V )Mobile phase B (per cent V/V )0-30100→500→5030-3150→1050→9031-351090Flow rate :2.3mL/min.Detection :spectrophotometer at 254nm.Injection :20μL.Identification:use the chromatogram supplied with teicoplaninfor identification CRS and the chromatogram obtained withreference solution (a)to identify the groups and impurities.Relative retention of groups and impurities with reference toteicoplanin A 2-2:—teicoplanin A 3group ≤0.70;—teicoplaninA 2group >0.70and ≤1.25and within this group:—teicoplanin A 2-2=1;—teicoplanin A 2-1group <1;—teicoplanin A 2-3group >1and <1.12;—teicoplanin A 2-4=about 1.12;—teicoplanin A 2-5group >1.12and ≤1.25;—impurities >1.25.Relative retention of principal peaks of the groups withreference to teicoplanin A 2-2(retentiontime =about 18min):teicoplanin A 3-1=about 0.43;teicoplanin A 2-1=about 0.93;teicoplanin A 2-3=about 1.04;teicoplanin A 2-4=about 1.12;teicoplanin A 2-5=about1.14.System suitability :reference solution (a):—the chromatogram obtained is similarto the chromatogramsupplied with teicoplanin for identification CRS ;—resolution :minimum 1.0between the peaks due to teicoplanin A2-4and teicoplanin A 2-5.Calculate the percentage content of the different components using the following equations:teicoplanin A 2group =teicoplanin A 2-2=teicoplanin A 2-1group =teicoplanin A 2-3group =teicoplanin A 2-4=teicoplanin A 2-5group =teicoplanin A 3group =impurities =S a =sum of the areas of the peaks due to teicoplanin A 2group in the chromatogram obtained with the test solution;S b =sum of the areas of the peaks due to teicoplanin A 3group in the chromatogram obtained with the test solution;disregard any peak due to mesityl oxide;S c =sumof the areas of the peaks with a relativeretention more than 1.25;S 1=sum of the areas of the peaks due to teicoplanin A 2-1group in the chromatogram obtained with the test solution;S 2=area of the peak due to teicoplanin A 2-2in thechromatogram obtained with the test solution;General Notices (1)apply to all monographs and other texts 3039Telmisartan EUROPEAN PHARMACOPOEIA7.0S 3=sum of the areas of the peaks due to teicoplanin A2-3 group in the chromatogram obtained with the testsolution;S 4=area of the peak due to teicoplanin A2-4in the chromatogram obtained with the test solution;S 5=sum of the areas of the peaks due to teicoplanin A2-5 group in the chromatogram obtained with the testsolution.Limits:—teicoplanin A2group:minimum80.0per cent;—teicoplanin A2-2:35.0per cent to55.0per cent;—teicoplanin A2-1group:maximum20.0per cent;—teicoplanin A2-3group:maximum20.0per cent;—teicoplanin A2-4:maximum20.0per cent;—teicoplanin A2-5group:maximum20.0per cent;—teicoplanin A3group:maximum15.0per cent;—total of impurities other than mesityl oxide with a relative retention more than1.25:maximum5.0per cent;—disregard limit:the area of the peak due to teicoplanin A2-2 in the chromatogram obtained with reference solution(b)(0.25per cent).Chlorides:maximum5.0per cent,expressed as sodium chloride (anhydrous substance).Dissolve1.000g in300mL of water R,stir and acidify with2mL of nitric acid R.Titrate with0.1M silver nitrate,determining the end-point potentiometrically(2.2.20).1mL of0.1M silver nitrate is equivalent to5.844mg of NaCl. Heavy metals(2.4.8):maximum20ppm.0.50g complies with test G.Prepare the reference solution using100μL of lead standard solution(100ppm Pb)R.Filter the solutions through a membrane filter(nominal pore size 0.45μm).Impurity A.Liquid chromatography(2.2.29)as described in the test for composition and related substances with the following modifications.Injection:20μL of the test solution and reference solution(c).Relative retention with reference to teicoplanin A2-2(retentiontime=about18min):impurity A=about0.6.Limits:—impurity A:maximum twice the area of the principal peak in the chromatogram obtained with reference solution(c)(0.2per cent).Water(2.5.12):maximum15.0per cent,determined on0.300g. Bacterial endotoxins(2.6.14):less than0.31IU/mg.ASSAYCarry out the microbiological assay of antibiotics(2.7.2),using the diffusion e teicoplanin CRS as the reference substance.STORAGEProtected from light,at a temperature of2°C to8°C.IMPURITIESSpecified impurities:A.A.4-methylpent-3-en-2-one(mesityl oxide).07/2008:2154corrected6.3TELMISARTANTelmisartanumC33H30N4O2Mr514.6 [144701-48-4]DEFINITION4′-[[4-Methyl-6-(1-methyl-1H-benzimidazol-2-yl)-2-propyl-1H-benzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid. Content:99.0per cent to101.0per cent(dried substance). CHARACTERSAppearance:white or slightly yellowish,crystalline powder. Solubility:practically insoluble in water,slightly soluble in methanol,sparingly soluble in methylene chloride.It dissolves in1M sodium hydroxide.It shows polymorphism(5.9).IDENTIFICATIONInfrared absorption spectrophotometry(2.2.24). Comparison:telmisartan CRS.If the spectra obtained in the solid state show differences, dissolve the substance to be examined and the reference substance separately in hot anhydrous ethanol R,evaporate to dryness and record new spectra using the residues.TESTSAppearance of solution.The solution is not more intensely coloured than reference solution Y4(2.2.2,Method II). Dissolve0.5g in1M sodium hydroxide and dilute to10mL with the same solvent.Related substances.Liquid chromatography(2.2.29).Test solution.To25mg of the substance to be examined add about5mL of methanol R and100μL of a40g/L solution of sodium hydroxide R.Dissolve with the aid of ultrasound and dilute to50mL with methanol R.Reference solution(a).Dilute1.0mL of the test solution to 10.0mL with methanol R.Dilute1.0mL of this solution to 100.0mL with methanol R.Reference solution(b).Dissolve the contents of a vial of telmisartan for system suitability CRS(containing impurities A,B,C,E and F)in2mL of methanol R.Reference solution(c).To5mg of telmisartan for peak identification CRS(containing impurity D)add about5mLof methanol R and100μL of a40g/L solution of sodium hydroxide R.Dissolve with the aid of ultrasound and dilute to 10mL with methanol R.Column:—size:l=0.125m,Ø=4.0mm;—stationary phase:octadecylsilyl silica gel forchromatography R(5μm)with a pore size of10nm;—temperature:40°C.3040See the information section on general monographs(cover pages)。

(完整版)美国药典USP31(921)翻译版(下)

(完整版)美国药典USP31(921)翻译版(下)

Method Ib (Residual Titration) 方法Ib(残留滴定)Principle— See the information given in the section Principle under Method Ia. In the residual titration, excess Reagent is added to the test specimen, sufficient time is allowed for the reaction to reach completion, and the unconsumed Reagent is titrated with a standard solution of water in a solvent such as methanol. The residual titration procedure is applicable generally and avoids the difficulties that may be encountered in the direct titration of substances from which the bound water is released slowly.原理:见方法Ia项下原理部分给出的信息。

在残留滴定中,额外的试剂被加入到供试样品中,为反应的完成留下了充分的时间,并且将未消耗掉的试剂与水和某种溶剂(例如,甲醇)的标准溶液一起滴定。

残留滴定程序通常是可行的,并避免了可能在直接滴定该物质过程中遇到的困难,这些物质中被束缚水分释放得很缓慢。

Apparatus, Reagent, and Test Preparation— Use Method Ia.仪器、试剂、供试配制液:同方法Ia。

Standardization of Water Solution for Residual Titration— Prepare a Water Solution by diluting 2 mL of water with methanol or other suitable solvent to 1000 mL. Standardize this solution by titrating 25.0 mL with the Reagent, previously standardized as directed under Standardization of the Reagent. Calculate the water content, in mg per mL, of the Water Solution taken by the formula:用于残留滴定的水溶液的标准化:以甲醇或其他适当溶剂将2mL水稀释至1000mL,以配制水溶液。

美国药典USP31-NF26无菌检查法《71》

美国药典USP31-NF26无菌检查法《71》

美国药典USP31-NF26无菌检查法《71》.doc71 STERILITY TESTS 无菌检查法Portions of this general chapter have been harmonized with the corresponding texts of the European Pharmacopeia and/or the Japanese Pharmacopeia. Those portions that are not harmonized are marked with symbols () to specify this fact.此通则的各部分已经与欧洲药典和/或日本药典的对应部分做了协调。

不一致的部分用符号()来标明。

The following procedures are applicable for determining whether a Pharmacopeial article purporting to be sterile complies with the requirements set forth in the individual monograph with respect to the test for sterility. Pharmacopeial articles are to be tested by the Membrane Filtration method under Test for Sterility of the Product to be Examined where the nature of the product permits. If the membrane filtration technique is unsuitable, use the Direct Inoculation of the Culture Medium method under Test for Sterility of the Product to be Examined. All devices, with the exception of Devices with Pathways Labeled Sterile, are tested using the Direct Inoculation of the Culture Medium method. Provisions for retesting are included under Observation and Interpretation of Results.下面这些步骤适用于测定是否某个用于无菌用途的药品是否符合其具体的各论中关于无菌检查的要求。

USPGC色谱柱规格对照(固定相)

USPGC色谱柱规格对照(固定相)

苯甲基二 四基聚 硅氧烷 (10%苯 取代)
35% phenyl-65% dimet hylpolysiloxane G42
(percentages refer to molar substitution).
35%苯基 -6 5%乙烯 基硅烷 (百分比 参见分 子取代 度)
6% cyanopropylphenyl-94% G43 dimethylpolysiloxane (percentages refer to
compound of polyethylene glycol with a G16
物粘合物 的高分 子合物 。[注- -- -商名 聚乙二
diepoxide linker.
醇合物 20M,或 Carbowax 20M,色谱试剂
[note—A vailable commercially as
商处购得]
G3
50% Phenyl-50% methylpolysiloxane.
50%苯基 -5 0%甲基 聚硅氧 烷
G4
Diethylene glycol succinate poly ester.
聚丁二酸 乙二醇 酯
G5
3-Cy anopropylpolysiloxane.
3-氰 丙基聚 氧硅烷
G6
Trifl uo rop ro pylmethylpolysiloxa ne.
25% 2-Cyanoethyl-75% G26
methylpolysiloxane.
25% 2-氰 基乙基 -7 5%甲 基聚硅 氧 烷
G27
5% Phenyl-95% methylpolysiloxane.
5%苯基- 95%甲 基聚硅 氧烷

美国药USP31-NF26药典规程的验证《1225》和药典规程的确认《1226》

美国药USP31-NF26药典规程的验证《1225》和药典规程的确认《1226》

<1225>V ALIDATION OF COMPENDIAL PROCEDURES药典规程的验证Test procedures for assessment of the quality levels of pharmaceutical articles are subject to various requirements. According to Section 501 of the Federal Food, Drug, and Cosmetic Act, assays and specifications in monographs of the United States Pharmacopeia and the National Formulary constitute legal standards. The Current Good Manufacturing Practice regulations [21 CFR 211.194(a)] require that test methods, which are used for assessing compliance of pharmaceutical articles with established specifications, must meet proper standards of accuracy and reliability. Also, according to these regulations [21 CFR 211.194(a)(2)], users of analytical methods described in USP-NF are not required to validate the accuracy and reliability of these methods, but merely verify their suitability under actual conditions of use. Recognizing the legal status of USP and NF standards, it is essential, therefore, that proposal for adoption of new or revised compendial analytical procedures be supported by sufficient laboratory data to document their validity.用于评价药物质量水平的测试规程受到多种要求的影响。

美国药典USP31翻译版

美国药典USP31翻译版

Many Pharmacopeial articles either are hydrates or contain water in adsorbed form. As a result, the determination of the water content is important in demonstrating compliance with the Pharmacopeial standards. Generally one of the methods given below is called for in the individual monograph, depending upon the nature of the article. In rare cases, a choice is allowed between two methods. When the article contains water of hydration, the Method I (Titrimetric), the Method II (Azeotropic), or the Method III (Gravimetric) is employed, as directed in the individual monograph, and the requirement is given under the heading Water.很多药典物品要么是水合物,要么含有处于吸附状态的水。

因此,测定水分含量对于证实与药典标准的符合性是很重要的。

通常,在具体的各论中会根据该物品的性质,要求使用下面若干方法中的一个。

偶尔,会允许在2个方法中任选一个。

当该物品含有水合状态的水,按照具体各论中的规定,使用方法I(滴定测量法)、方法II(恒沸测量法)、或方法III(重量分析法),这个要求在标题水分项下给出。

usp美国药典等级

usp美国药典等级

usp美国药典等级美国药典级usp calss vi美国药典级(usp)实际上含义:美国药典(usp)是一个非政府组织,通过建立最新的标准来保证药品和其他保健技术的质量,从而支持公共卫生。

该组织与制药和生物技术行业有关。

美国药典规定了质量、纯度、强度和一致性的标准。

这些usp 标准发表在《美国药典》和《国家处方集》(usp nf)中。

usp第四类产品经过一系列的生物试验。

usp第六类化合物必须由具有明确生物相容性历史的成分制成,以满足对渗滤液的严格要求。

动物用来测试材料的毒性。

急性毒性试验:该试验测量试验材料的刺激性,控制其对人体的潜在危害。

毒性由口腔、皮肤和吸入决定。

皮内试验:这种特殊的试验将材料直接注射到正常使用过程中接触到的组织中,不保护皮肤或任何其他身体系统。

这将允许测试团队评估特定组织对材料的响应。

植入试验:植入试验确定植入活体动物时活体组织对材料的反应。

usp六级试验所需的标准植入时间为5天。

如果在5天后没有刺激或毒性的迹象,它将满足试验的植入要求。

温度和时间:用于全身毒性和皮内试验的材料提取物固定在设定的温度和暴露时间,以确保结果符合通用标准。

用三种不同的温度和时间暴露条件处理所有的材料提取物。

前72小时在122°F或50°C下给药,然后在158°F下给药24小时,最后在250°F下给药1小时。

usp第六类塑料试验旨在评价各种塑料材料在体内的生物反应性。

为了测试药物容器,塑料类测试经常在未焊接的塑料树脂和容器上进行。

类塑料测试不是生物相容性测试的替代品,但通常被制造商用来对材料进行分类。

塑料的分类包括三种体内试验。

系统注射试验和皮内试验旨在通过单剂量注射特定提取物来控制对塑料和其他聚合物的全身和局部生物反应。

第三种测试,即植入测试,旨在评估活组织对测试材料的反应。

利用这三个试验和不同提取物的不同排列,完成了六个不同等级的塑料等级试验。

usp定义了六种塑料类别,从i到vi(vi仍然是最严格的)。

甜菜碱盐酸盐USP32检测方式

甜菜碱盐酸盐USP32检测方式

甜菜碱盐酸盐USP32检测方式和标准依照客户提供的资料,翻译情形如下:无水基础上测得甜菜碱盐酸盐含量:98%-100.5%包装和贮存:密闭性好的容器美国药典USP标准参考:辨别:A,红外线吸收(197)B,1比20的溶液符合氯化物的检测要求PH(791): PH 值应为0.8-1.2之间,溶液比为1:10水分测定,方式1(921):不超过0.5%炽灼残渣(281):不超过0.1%重金属(231):0.001%主含量:转移400mg精准称重过的甜菜碱盐酸盐到一个锥形瓶,加50ml冰乙酸,加热并搅拌直到溶液完全溶解,加入50ml乙酸汞检测溶液,冷的,加2滴结晶紫检测溶液,然后用0.1当量浓度的高氯酸滴定液滴定至一个绿色结点,进行一个空白对照,并做一些必要修正,每ml0.1当量浓度高氯酸相当于15.36mg甜菜碱盐酸盐。

<197> 分光光度辨别查验分光光度法检测关于很多药典化学物质的辨别做出了意味深远的奉献。

下面的这些步骤适用于那些吸收红外和/或紫外线的物质(见分光光度测定法和光散射<851>)。

一个物质的红外吸收光谱,在与从对应的USP标准品处获得的光谱图进行比较后,或许提供了从任何单一检验中所能获得的关于该物质的鉴别的最具决定性的证据。

而另一方面,紫外吸收图谱则并未展示出高度的特异性。

与红外吸收和紫外吸收检验标准的符合性,如在很大比例的药典专论中所要求的,用于供试样品的鉴别几乎不会导致任何质疑。

红外吸收光谱μm至15μm(3800 cm–1至650 cm–1)的光谱范围内记录供试样品和对应的USP标准品的光谱。

除非有另外的规定或该标准品利用前无需干燥,供试样品应在为对应标准品规定的条件下预先进行干燥。

只有当对应USP标准品依照类似方式进行了前处置,且在一样波长的情形下,前处置后的供试样品的红外吸收图谱才能展现出最大值。

在这样得到的光谱中有可能观察到差异,这些差异有时候是由于同质异像体的存在,这种情况并非总是可以接受的(见分光光度测定法和光散射<851>中的步骤项的规定)。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

CarrageenanCarrageenan.Carrageenan [9000-07-1].» Carrageenan is the hydrocolloid obtained by extraction with water or aqueous alkali, from some members of the class Rhodophyceae (red seaweeds). Carrageenan consists chiefly of potassium, sodium, calcium, magnesium, and ammonium sulfate esters of galactose and 3,6-anhydrogalactose copolymers. These hexoses are alternately linked -1,3 and -1,4 in the polymer. The prevalent copolymers in the hydrocolloid are designated kappa-, iota-, and lambda-carrageenan. Kappa-carrageenan is mostly the alternating polymer of D-galactose-4-sulfate and 3,6-anhydro-D-galactose. Iota-carrageenan is similar, except that the 3,6-anhydrogalactose is sulfated at carbon 2. Between kappa-carrageenan and iota-carrageenan there is a continuum of intermediate compositions differing in degree of sulfation at carbon 2. In lambda-carrageenan, the alternating monomeric units are mostly D-galactose-2-sulfate (1,3-linked) and D-galactose-2,6-disulfate (1,4-linked). The ester sulfate content for Carrageenan ranges from 18 percent to 40 percent. In addition, it contains inorganic salts that originate from the seaweed and from the process of recovery from the extract.Carrageenan is recovered by alcohol precipitation, by drum drying, or by freezing. The alcohols used during recovery and purification are restricted to methanol, alcohol, and isopropyl alcohol. Carrageenan that is recovered by drum-roll drying may contain mono- and di-glycerides or up to 5 percent of polysorbate 80 used as roll-stripping agents.Packaging and storage— Preserve in tight containers, preferably in a cool place. Solubility in water— Not more than 30 mL of water is required to dissolve 1 g at a temperature of 80.Identification—A: A solution (1 in 50) prepared by heating a uniform dispersion in a hot water bath to 80 (Solution A) becomes more viscous upon cooling and may form a gel.B: To 10 mL of Solution A, while still hot, add 4 drops of potassium chloride solution (1 in 10), mix, and cool. A short-textured (“brittle”) gel indicates a carrageenan of a predominantly kappa type; a compliant (“elastic”) gel indicates a predominantly iota type. If the solution does not gel, the carrageenan is of a predominantly lambda type.C: Dilute a portion of Solution A with about 4 parts of water, and add 2 to 3 drops of methylene blue TS: a blue, stringy precipitate is formed (also positive for furcellaran, asimilar colloid).D: Obtain IR absorption spectra on the gelling and non-gelling fractions of the specimen by the following procedure. Disperse 2 g in 200 mL of potassium chloride solution (1 in40), and stir for 1 hour. Allow to stand for 18 hours, stir again for 1 hour, and transfer to a centrifuge tube. (If the transfer cannot be made because the dispersion is too viscous, dilute with up to 200 mL of the potassium chloride solution.) Centrifuge at approximately 1000 g for 15 minutes.Remove the clear supernatant, resuspend the residue in 200 mL of potassium chloride solution (1 in 40), and centrifuge again. Coagulate the combined supernatants by adding 2 volumes of dilute alcohol (9 in 10). (Retain the sediment for use subsequently asdirected.) Recover the coagulum, and wash with 250 mL of the dilute alcohol. Press the excess liquid from the coagulum, and dry it at 60 for 2 hours: the material so obtained is the nongelling fraction (lambda carrageenan).Disperse the sediment retained from the foregoing procedure in 250 mL of cold water, heat at 90 for 10 minutes, and cool to 60. Coagulate the mixture, then recover, wash, and dry the coagulum as described above: the material so obtained is the gelling fraction (kappa- and iota -carrageenan).Prepare a solution (1 in 500) of each fraction, cast films 5 µm thick (when dry) on a suitable nonsticking surface, and obtain the IR absorption spectrum of each film.Carrageenan has strong, broad absorption bands, typical of all polysaccharides, in the 1000 to 1100 cm 1 region. Absorption maxima are 1065 cm 1 and 1020 cm 1 for gelling and nongelling types, respectively. Other characteristic absorption bands and their intensities relative to the absorbance at 1050 cm1 are as shown in the accompanying table. Viscosity 911— Transfer 7.5 g to a tared, tall-form, 600-mL beaker, add 450 mL of water, and disperse with agitation for about 15 minutes. Add water to bring the weight to 500 g, and heat in a water bath, with continuous agitation, until a temperature of 80 is reached. Add water to adjust for loss by evaporation, cool to between 76 and 77, and place in a constant-temperature bath maintained at 75. Provide a suitable rotationalWave Number cm 1Molecular Assignment Absorbance Relative to 1050 cm 1Kappa Iota Lambda 1220 to 1260Ester sulfate 0.7 to 1.2 1.2 to 1.6 1.4 to 2.0928 to 9333,6-anhydrogalactose 0.3 to 0.60.2 to 0.40 to 0.2840 to 850Galactose-4-sulfate 0.3 to 0.50.2 to 0.4—825 to 830Galactose-2-sulfate ——0.2 to 0.4810 to 820Galactose-6-sulfate ——0.1 to 0.3800 to 8053,6-anhydrogalactose-2-sulfate 0 to 0.20.2 to 0.4—viscosimeter with a spindle 1.88 cm in diameter and 6.51 cm high, using an immersion depth of 8.10 cm (No. 1 spindle). Allow the spindle to rotate in the solution at 30 rpm for 6 revolutions, then observe the scale reading. Convert the scale reading to centipoises by multiplying by the constant for the spindle and speed employed. The viscosity at 75is not less than 5 centipoises. Microbial limits 61— The total bacterial count does not exceed 200 cfu per g, and the tests for Salmonella species and Escherichia coli are negative. Loss on drying 731— Dry it at a pressure not exceeding 10 mm of mercury at 70for 18 hours, cool in a desiccator, and weigh: it loses not more than 12.5% of its weight. Acid-insoluble matter— Transfer about 2 g, accurately weighed, to a 250-mL beaker containing 150 mL of water and 1.5 mL of sulfuric acid. Cover with a watch glass, and heat on a steam bath for 6 hours, rubbing down the wall of the beaker frequently with a rubber-tipped stirring rod, and replacing any water lost by evaporation. Transfer about 500 mg of a suitable filter aid, accurately weighed, to the beaker, and filter through a tared filtering crucible provided with a 2.4-cm glass fiber filter. Wash the residue several times with hot water, dry at 105 for 3 hours, cool in a desiccator, and weigh. The difference between the total weight and the sum of the weights of the filter aid, crucible, and glass fiber filter is the weight of the acid-insoluble matter. It is not more than 2.0% of the weight of Carrageenan taken. Total ash 561: not more than 35.0%. Arsenic 211: 3 ppm. Lead 251: 0.001%.Heavy metals, Method II 231: 0.004%.Auxiliary Information— Before contacting USP, have you checked for your question in the FAQs ?USP31–NF26 Page 1102Chromatographic Column— CARRAGEENANChromatographic columns text is not derived from, and not part of, USP 31 or NF 26. Topic/Question ContactExpert Committee Monograph Hong Wang, Ph.D.Scientist1-301-816-8351(EM205) Excipient Monographs 261Radhakrishna S Tirumalai, Ph.D.Scientist1-301-816-8339(MSA05) Microbiology and Sterility Assurance。

相关文档
最新文档